Trial Filter

BETA

An intelligent search tool for clinical trials

Sign In
Back|NCT05978141Recruiting
Official Title

The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens

Sponsor
Memorial Sloan Kettering Cancer Center
Enrollment
1,000
Timeline
Jul 2023 → Jul 2030
About This Study

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Eligibility Criteria

Inclusion Criteria

  • 1Written informed consent
  • 2Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
  • 3Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):
  • 4T-cell prolymphocytic leukemia
  • 5T-cell large granular lymphocytic leukemia
  • 6Chronic lymphoproliferative disorder of NK cells
  • 7Aggressive NK-cell leukemia
  • 8Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
  • 9Chronic active EBV infection of T- and NK-cell type, systemic form
  • 10Hydroa vacciniforme-like lymphoproliferative disorder
  • 11Adult T-cell leukemia/lymphoma
  • 12Extranodal NK/T-cell lymphoma, nasal type
  • 13Enteropathy-associated T-cell lymphoma
  • 14Monomorphic epitheliotropic intestinal T-cell lymphoma
  • 15Intestinal T-cell lymphoma, not otherwise specified (NOS)
  • 16Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
  • 17Hepatosplenic T-cell lymphoma
  • 18Subcutaneous panniculitis-like T-cell lymphoma
  • 19Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
  • 20Sézary syndrome
  • 21Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
  • 22Primary cutaneous Gamma-Delta T-cell lymphoma
  • 23Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
  • 24Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
  • 25Peripheral T-cell lymphoma, not otherwise specified
  • 26Angioimmunoblastic T-cell lymphoma
  • 27Follicular T-cell lymphoma
  • 28Nodal peripheral T-cell lymphoma with TFH phenotype
  • 29Anaplastic large cell lymphoma, ALK-positive
  • 30Anaplastic large cell lymphoma, ALK-negative
  • 31Breast-implant associated anaplastic large cell lymphoma.
  • 32NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.

Exclusion Criteria

  • 1Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
  • 2Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

Locations

26 sites participating in this study

Emory University (Data Collection Only)

Atlanta, Georgia 30322

Recruiting

Pamela Allen, MD, MSc

404-778-0519

City of Hope Cancer Center (Data collection only)

Duarte, California 91010

Recruiting

Jasmine Zain, MD

626-359-8111

UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only)

San Diego, California 92103

Recruiting

Aaron Goodman, MD

858-822-6100
Data sourced from ClinicalTrials.govView on ClinicalTrials.gov →